Abstract
Many growth factors including epidermal growth factor (EGF) induce tyrosine phosphorylation of the c-Cbl proto-oncogene product, whose function, however, remains unclear. Recently, Sli-1, a Caenorhabditis elegans homologue of c-Cbl, was found to be a negative regulator of let-23-mediated vulval induction pathway, suggesting that c-Cbl may negatively regulate EGF receptor (EGFR)-mediated signaling. In this study, by an antisense RNA approach, we examined the effects of expression level of c-Cbl on EGFR signaling and showed that overexpression of c-Cbl reduces and antisense repression of c-Cbl enhances autophosphorylation of EGF receptors and activation of the JAK-STAT pathway. However, in contrast to the Sli-1 protein, the expressed amount of c-Cbl does not affect activation of the Ras pathway, suggesting that the EGFR-mediated signaling pathways are differently regulated by c-Cbl among nematodes and mammals.
Highlights
The c-Cbl proto-oncogene was originally identified as a cellular homologue of v-Cbl oncogene, which was cloned from the Cas NS-1 murine leukemia virus [1]
We introduced them into NIH3T3 cells, and the cells were subjected to the G418 selection
The expression levels of c-Cbl in these cell lines were examined by the immunoblot with anti-cCbl antibody
Summary
The c-Cbl proto-oncogene was originally identified as a cellular homologue of v-Cbl oncogene, which was cloned from the Cas NS-1 murine leukemia virus [1]. The c-Cbl gene product is a 120-kDa protein that contains an NH2-terminal domain with a nuclear localization signal, followed by a RING finger motif [2]. We established a subline of NIH3T3 cells in which the expression of c-Cbl is repressed by the introduction of antisense c-Cbl cDNA. By using this cell line as well as the parental NIH3T3 cells and c-Cbl-overexpressing cells, we analyzed the roles of c-Cbl in regulation of the EGFR signaling
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.